ibuprofen (ibuprofen, Scherer)
✓ ApprovedCardinal Health, Inc. · PTGS1 · 小分子
什么是 ibuprofen?
ibuprofen 是一种小分子,由Cardinal Health, Inc.研发。该药已获批,用于治疗相关适应症,给药途径:Topical。
药物档案
| 商品名 | ibuprofen, Scherer |
| 公司 | Cardinal Health, Inc. |
| 药物类别 | 小分子 |
| 分子靶点 | PTGS1, PTGS2 |
| 给药途径 | Topical |
| 状态 | Approved |
作用机制
分子靶点
ibuprofen 作用于 2 个分子靶点:
| PTGS1 | prostaglandin-endoperoxide synthase 1 (COX3, PCOX1) |
| PTGS2 | prostaglandin-endoperoxide synthase 2 (GRIPGHS, hCox-2) |
治疗适应症
ibuprofen 针对 3 个适应症,涉及 2 个治疗领域。
| 治疗领域 | 疾病/病症 | 分期 |
|---|---|---|
| Gastrointestinal disorders | Abdominal pain | ✓ Approved |
| Musculoskeletal and connective tissue disorders | Musculoskeletal pain | ✓ Approved |
| Musculoskeletal and connective tissue disorders | Rheumatoid arthritis | ✓ Approved |
相关研究文献
Vanishing bile duct syndrome reports and recorded fatal outcomes in FAERS: a disproportionality analysis.
Yin Yi Y, Zhang Guiju G
Vanishing bile duct syndrome (VBDS) is a rare but life-threatening condition characterized by progressive destruction of intrahepatic bile ducts, often leading to cirrhosis and death. Large-scale pharmacovigilance studies systematically investigating VBDS reports, particularly those with reported fatal outcomes, remain scarce. We conducted a disproportionality analysis of the FDA Adverse Event Reporting System (FAERS) database (2004 Q1-2025 Q4). VBDS reports were identified using the MedDRA preferred term "Vanishing bile duct syndrome" (Code 10054753). We applied four algorithms-reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCPNN), and empirical Bayesian geometric mean (EBGM). A positive signal required meeting criteria for all four methods simultaneously. For drugs meeting signal criteria, we further performed a two-dimensional cross-analysis by intersecting drugs with the highest total report counts and those with the highest death counts, to identify drugs appearing in both top-10 rankings. After deduplication, 19,588,161 unique adverse event reports were available, among which 997 reports coded as VBDS were identified. A death outcome was recorded in 193 reports (19.36%); this proportion reflects FAERS reporting patterns and should not be interpreted as VBDS-attributable mortality or a clinical case-fatality estimate. Disproportionality analysis identified 48 drugs meeting all four signal criteria. Notably, only carbamazepine explicitly mentioned VBDS in its FDA label, and merely 18 of the 48 drugs included the broader term "cholestasis". Through cross-analysis of total report counts and reported death counts, six drugs appeared in both top-10 ranking lists: ibuprofen, ciprofloxacin, azithromycin, sulfamethoxazole-trimethoprim, avacopan, and celecoxib. This large-scale pharmacovigilance analysis of FAERS suggests the mention of VBDS among FDA product labels differs across drugs generating post-marketing safety signals, and that this difference warrants further regulatory and clinical evaluation. Six agents (ibuprofen, ciprofloxacin, azithromycin, sulfamethoxazole-trimethoprim, avacopan, celecoxib) appeared in both top-10 ranking lists for total VBDS reports and reported death counts. Because these rankings are based on descriptive absolute FAERS report counts, these agents warrant further clinical and pharmacovigilance evaluation, particularly in patients with pre-existing risk factors for DILI. These findings may support pharmacovigilance surveillance and hypothesis generation, but should be interpreted as reporting associations rather than the evidence of causality.
Potential Effects of Nonantibiotic Emerging Contaminant Degradation on Antibiotic Resistance Genes in Effluent-Impacted Hyporheic Zones.
Xie Yue Y, Jin Zepeng Z, Wang Dianqi D, Su Ting T et al.
Hyporheic zones (HZs) are hotspots of antibiotic resistance genes (ARGs) in rivers. Nonantibiotic emerging contaminants (ECs) discharged from wastewater treatment plants (WWTPs) can exert selective pressure on microbial communities and contribute to ARGs dissemination. However, the role of microbial ECs degradation in ARGs dissemination through co-selection remains poorly understood. In this study, HZs sediment samples were collected from two rivers dominated by WWTPs effluent and analyzed using metagenomic sequencing to investigate the co-selection effects of ECs on ARGs. A custom database of ECs degradation genes (ECDGs) was constructed by integrating information from EnviPath, KEGG Xenobiotics modules, and Eawag-BBD, totally covering 187 contaminants. Using this database, ECDGs associated with 78 ECs were identified, with genes associated with industrial pollutants predominating. After samples affected by a WWTP shutdown were excluded, ARGs and ECDGs were significantly correlated across both rivers and seasons (p < 0.05). Network analysis identified 11 potential ECDGs hosts that were also associated with ARGs, with Phenylobacterium being the most abundant genus. Co-localization analysis revealed 3824 contigs harboring both ARGs and ECDGs, of which 2395 were identified as plasmid-like sequences. These findings suggest widespread potential for co-resistance involving ARGs and ECDGs. In addition, a total of 4250 open reading frames (ORFs) were identified as having cross-resistance potential. Analysis of reconstructed metagenome-assembled genomes recovered complete pathways for kanamycin resistance and ibuprofen degradation that shared an ORF. These site-specific results provide genomic evidence that ECs discharged from WWTPs could promote ARGs dissemination through co-selection in HZs.
The Convergent Renal Insult: Why Endurance Athletes' Self-Medication With Nonsteroidal Anti-Inflammatory Drugs Requires a Sport-Specific Risk Model-A Narrative Review From Pharmaceutical and Sport-Science Perspectives.
Will Andreas A
Nonsteroidal anti-inflammatory drugs (NSAIDs) are the most widely consumed pharmacological agents in endurance sport, with reported prevalence of 14.8%-88% and consumption dominated by prophylactic rather than therapeutic intent despite three meta-analyses demonstrating no ergogenic effect. This use is sustained by a decision architecture in which pain is reframed as a controllable barrier to performance, prophylactic dosing is normalized within the training group, and renal risk is systematically underestimated: Among IRONMAN triathletes, only 27% were aware of it. This narrative review reframes the safety problem around the kidney. During prolonged high-intensity exercise, three stressors converge: sympathetic renal vasoconstriction, progressive dehydration activating the renin-angiotensin-aldosterone system, and NSAID-mediated prostaglandin inhibition, removing the compensatory vasodilatory safety net. This sport-specific convergent renal insult differs structurally from the clinical triple whammy because the first two stressors are intrinsic to the activity itself. The clinical manifestation appears intensity- and duration-dependent: Ibuprofen increased acute kidney injury rates from 34% to 52% during an 80-km ultramarathon stage (NNH 5.5; not statistically significant) but did not amplify biomarker responses during one hour of moderate running. Whether repeated transient insults accumulate into chronic kidney disease, as established for occupational heat-stress nephropathy and for hospital-documented AKI, remains the central unanswered question for habitual athletic NSAID users. Among the guideline documents reviewed, none currently addresses habitual over-the-counter NSAID use under exercise-induced renal stress in healthy athletes. The epidemiology and decision architecture of repeated exposure, the renal evidence base, the cumulative-exposure question, and the gap in current guidance together define future research needs for endurance-sport analgesic pharmacovigilance.
Soft-sprayed sodium alginate/cellulose nanofibril hydrogel membrane for temporally differentiated curcumin/ibuprofen release and enhanced infected wound healing.
Li Yuhang Y, Gao Xing X, Lu Xiaotong X, Fu Yuanlin Y et al.
Infected wound healing requires both effective early infection control and sustained regulation of the inflammatory microenvironment, while conventional prefabricated dressings often provide limited adaptability to irregular wound surfaces. Here, we developed a soft-sprayed sodium alginate/cellulose nanofibril hydrogel membrane (CUR@IC/SA) integrating conformal in-situ formation with temporally differentiated curcumin (CUR) and ibuprofen (IBU) release. CUR was encapsulated in Pluronic F127 nanomicelles and physically confined within the hydrogel network, enabling rapid release for early antibacterial and antioxidant intervention. In contrast, IBU was covalently grafted onto cellulose nanofibrils through hydrolyzable ester linkages, resulting in prolonged hydrolysis-mediated release. The precursor was deposited by low-impetus ultrasonic spraying and rapidly crosslinked by Cu2+ to form a self-supporting hydrogel membrane, which could also be formed directly on irregular wound surfaces. The optimized CUR@IC/SA membrane exhibited favorable porous structure, mechanical flexibility, fluid-management capability, short-term in vitro cytocompatibility, and wet-tissue interfacial stability. In vitro, CUR@IC/SA showed strong antibacterial activity against Staphylococcus aureus and Escherichia coli, with inhibition rates of approximately 99.8%, together with pronounced radical-scavenging activity. In an S. aureus-infected mouse wound model, CUR@IC/SA significantly reduced the early bacterial burden and achieved approximately 97% wound closure by day 13. Histological and immunohistochemical analyses further indicated improved tissue repair and reduced local inflammatory responses. Transcriptomic analysis revealed broad treatment-associated changes in inflammation- and repair-related transcriptional programs, including NF-κB-associated signaling. Overall, this work demonstrates a soft-spray hydrogel platform that couples conformal wound coverage with temporally differentiated therapeutic release for infected wound management.
A case of suspected IgE-mediated hypersensitivity to Menta piperita with identification of a possible allergenic protein through proteomic study.
Jurgens Yanina Y, Schayman Waleska W, Hernández Dolores D, Cases Bárbara B et al.
Products derived from Mentha piperita (peppermint) and Mentha spicata (spearmint) are commonly used in cosmetics and food preparation, as well as in medications for treating various gastrointestinal, cardiovascular, and respiratory disorders. A 41-year-old male patient of Italian origin was evaluated for recurrent symptoms of urticaria; he had a history of allergic rhinoconjunctivitis caused by house dust mites (Dermatophagoides pteronyssinus and Dermatophagoides farinae). During the first episode, he reported generalized urticaria 20 minutes after taking mint-flavored granulated ibuprofen (Espidifen® 600 mg), requiring emergency medical attention. In the second episode, one month later, he experienced nasal obstruction, sneezing, and rhinorrhea after chewing mint-flavored gum. In the third episode, occurring weeks later, he suffered two bouts of contact dermatitis after applying an anti-inflammatory cream containing menthol and using a mentholated shampoo. All symptoms resolved upon complete avoidance of mint-containing products. Skin prick-to-prick testing (using fresh leaves) was performed with various species from the Lamiaceae family. Only the fresh M. piperita leaf elicited a positive reaction (5 mm wheal and 4 mm erythema). Tests with basil, oregano, and thyme were negative. Molecular diagnosis (specific IgE) confirmed the reaction to M. piperita (0.4 kU/L). Given the widespread use of mint derivatives in various forms, sensitization to mint may be underdiagnosed. Mint allergy should be considered-specifically regarding potential IgE-mediated reactions-in patients with unclear diagnoses following exposure to mint-containing products.
注册免费账户还可查看另外 9996 篇文献
免费注册查看全部文献 →